

Approved on 15 March 2022

The Board:

1. Approves the revised budget recommended for the grants listed in Table 2 of GF/B46/ER11 ("Table 2");
2. Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, and (b) is subject to the availability of funding; and
3. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

This decision does not have material budgetary implications for operating expenses.

**Table 2: Secretariat's Recommendation on Additional Funding to Finance UQD from the 2017-2019 Allocation Period**

Please note that each country name is [linked](#) to the extranet site where supporting documents are available for review

<b>N</b>	<b>Applicant</b>	<b>Disease Component</b>	<b>Grant Name</b>	<b>Additional Funding Source</b>	<b>Currency</b>	<b>Previously Approved Program Budget</b>	<b>Recommended Additional Funding</b>	<b>Revised Program Budget</b>
1	<a href="#">Paraguay</a>	TB	PRY-T-AV	Portfolio Optimization	US\$	3,245,058	610,911	3,855,969
2	<a href="#">Romania</a>	TB	ROU-T-MOH	Portfolio Optimization	EUR	3,590,075	1,737,261	5,327,336